When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Asparagine endopeptidase (AEP), an enzyme already identified as a contributor to the tangling of tau proteins and increasing neurotoxicity in Alzheimer’s cases, is now also believed to activate…
The Crisalix System was developed to help patients visualize their post-operative breast reconstruction’s potential aesthetic outcome prior to surgery. Some surgeons find it invaluable in explaining the important…
Traditionally, men have been more likely to be diagnosed with Parkinson disease. However, as people continue to live longer, cases of female patients with PD are becoming more…
Approximately one-third of patients with Huntington’s disease (HD) experience depression. In 21 published case reports where electroconvulsive therapy (ECT) was used to treat depression in patients with HD,…
Making use of the many readily accessible resources and services available to both physicians and patients can help alleviate awkwardness that may arise when discussing the subject of…
Many important properties and potential health benefits of nicotinamide riboside have been identified since discovery of its role in the human NAD metabolic cycle over a decade ago.
